Estudo de dose e perfil lipo e apoproteico da indoramina em pacientes hipertensos

Martinez, Tânia Leme da Rocha; Wortsman, Arnaldo Moisés; Auriemo, Caio Roberto Chimenti; Delboni Filho, Humberto; Zymberg, Milton; Pires, Lilian Guidugli; Feres, Marcia Cristina; Maldjan, Suely; Piageti, Ana Luiza Araújo; Cunha, Maria Adelaide.
Folha méd ; 91(1): 29-33, jul. 1985. tab
Artículo en Portugués | LILACS | ID: lil-30614

Documentos relacionados

  1. Indoramin in the treatment of hypertension: a placebo controlled trial.
  2. Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.
  3. [Relationship between lipid profile and body mass index. Five-year follow-up in children aged 6-11 years old. The Rivas-Vaciamadrid study].
  4. Is there any correlation between platelet aggregation, plasma lipoproteins, apoproteins and membrane fluidity of human blood platelets?
  5. [Procedures of examination and diagnosis to differentiate hypertriglyceridemia].
  6. Indoramin for hypertension.
  7. Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients.
  8. Apoproteins and lipids as discriminators of severity of coronary heart disease.
  9. Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals.
  10. [Use of ultrafiltration to obtain serum devoid of lipoproteins].